Decibel Therapeutics, a clinical-stage biotechnology company developing novel restorative gene therapeutics to treat hearing loss and balance disorders, has closed an oversubscribed Series D financing, which raised $82.2M.

The round was led by OrbiMed, with new investments from BlackRock Health Sciences, Casdin Capital, Janus Henderson, Samsara BioCapital and Surveyor Capital (a Citadel company). Existing investors also participated in the financing, including Foresite Capital, GV, S-Cubed Capital, Sobrato Capital, SR One, Third Rock Ventures and other institutional investors.

Decibel Therapeutics is a hearing company focused on discovering and developing new medicines to protect, repair and restore hearing. By combining recent innovations in hearing science with leading diagnostic tools, biological insights, modeling and therapeutic delivery techniques, Decibel is pioneering a comprehensive approach to define the underlying biological causes of hearing loss and develop a pipeline of breakthrough drugs targeted to specific indications and patients.